The Future of Dermatology

📋 Summary:In this special behind-the-scenes episode, Dr. Faranak Kamangar welcomes podcast producer Steph Cullen on camera for the first time in two years. Together they reflect on over three years of building the Future of Dermatology podcast, now a top dermatology-facing podcast with 130+ episodes, 40,000+ total plays across all platforms, and over 700 downloads a month, all achieved with zero paid marketing. Dr. Kamangar shares exciting updates happening this summer, including the opening of her new Palo Alto practice in August, the upcoming SF Derm 2026 conference (August 28–30 at the Four Seasons Silicon Valley in Palo Alto), and the explosive growth of DermGPT, her AI tool built specifically for dermatologists and derm providers. She also celebrates her recognition on the Inc. Female Founders 500 list for her work in health tech AI. The conversation covers what makes this podcast stand out - a steadfast commitment to evidence-based, science-forward dermatology content - and looks ahead to the future, including expanding the guest roster geographically, a possible move into short-form content, and a growing focus on AI in dermatology. Whether you're a longtime listener or just discovering the show, this episode is a candid, energetic look at what's been built and what's coming next. Register for SF Derm 2026! https://www.sfderm.org/ ✅ Key Takeaways: 1. The podcast has grown organically to become a top dermatology-facing show. With 130+ episodes, 40,000+ total plays, and over 700 monthly downloads across Spotify, Apple, and YouTube - all without paid promotion or leaderboard platforms - the Future of Dermatology has become one of the most listened-to dermatology podcasts available. 2. Staying science-first has been the secret to longevity. Dr. Kamangar and Steph emphasize that resisting the temptation to chase trending or sensational topics in favor of solid, evidence-based science is what built a loyal, engaged audience of dermatologists, providers, and interested listeners. 3. SF Derm 2026 is shaping up to be the biggest one yet. The conference runs August 28–30 at the Four Seasons Silicon Valley in Palo Alto. Highlights include a tech-forward AI and derm panel featuring physicians from Stanford and Harvard, a metabolic and HS/vulvar disease panel, a hormones talk by an OB-GYN, grand rounds, resident jeopardy, and a Saturday night "1001 Nights" themed party. 4. DermGPT has reached over 23,000 dermatology providers - with more than 5,000 using it regularly - built by a team of just three people with no marketing budget. Dr. Kamangar built this tool out of a recognized need: dermatology makes up less than 2% of the house of medicine, making it an overlooked target for health tech development, yet burnout from administrative burden is high. 5. AI is about giving doctors time back, not replacing them. The episode makes a compelling case that AI tools like DermGPT are most valuable not for replacing clinical judgment, but for reducing "pajama time" - the hours physicians spend on documentation and inbox management after hours - so they can focus on the work they're most passionate about. 6. The podcast has begun influencing larger media. A patient episode on atopic dermatitis caught the attention of Time Health, who reached out to feature the guest. This kind of organic mainstream crossover validates the show's mission to bring credible dermatology science to wider audiences. 7. There are dermatology deserts across the U.S. The episode briefly touches on geographic disparities in dermatology access, with Steph noting the growing need for telehealth solutions. Dr. Kamangar acknowledges the podcast's current West Coast bias and invites listeners to recommend guests from underrepresented regions. 🕐 Chapters:00:00:01 — Welcome & Introduction00:00:54 — Meet Steph Cullen: The Face Behind the Scenes00:02:33 — Three Years, 130+ Episodes & 40,000 Plays00:04:53 — Why Staying Science-Forward Has Paid Off00:07:15 — SF

Summary This podcast episode delves into the complexities of radiation dermatitis, a common side effect of cancer treatment affecting up to 95% of patients. Dr. Shira Lipton discusses the prevalence, mechanisms, and phases of radiation damage, differentiating between acute and chronic radiation dermatitis. The episode emphasizes the importance of early intervention, patient management strategies, and the need for ongoing monitoring to mitigate long-term effects. Key takeaways include the significance of understanding patient risk factors and the role of multidisciplinary care in managing skin health during and after radiation therapy. Takeaways - Radiation dermatitis is a common side effect of cancer treatment.- Up to 95% of breast cancer patients experience skin reactions.- Understanding genetic factors can help identify high-risk patients.- Weight management can improve healing during radiation therapy.- Symptoms of radiation dermatitis typically worsen over time.- Moist desquamation is a severe form of radiation dermatitis.- Chronic changes can develop long after treatment ends.- Sun protection is essential for patients with radiation dermatitis.- Early intervention can prevent chronic complications.- Multidisciplinary care is crucial for effective management. Chapters 00:00 - Introduction to Radiation Dermatitis02:48 - Understanding Radiation Dermatitis and Its Impact05:41 - Acute vs. Chronic Radiation Dermatitis08:28 - Management and Treatment Strategies11:19 - Rare Complications and Long-term Effects13:21 - Conclusion and Key Takeaways

Summary In this truncated replay from the 2025 SF Derm Annual Conference, Dr. David Cotter discusses the implications of latent tuberculosis in dermatology, particularly in psoriasis treatment. He highlights the prevalence of latent TB, risk factors, and the importance of targeted screening. This session also addresses the mental health challenges faced by psoriasis patients and evaluates the safety of new treatments, emphasizing the need for careful monitoring and patient support. Takeaways - The prevalence of latent TB infection in the U.S. is 5%.- Healthcare workers have a higher risk of latent TB.- Patients on TNF inhibitors are significantly more likely to develop active TB.- Screening for latent TB should be targeted to high-risk patients.- Annual TB screening is not necessary for most psoriasis patients on IL-17 and IL-23 inhibitors.- The cost of screening for latent TB can be substantial.- Patients with psoriasis have higher rates of suicidal ideation and behavior.- Effective psoriasis treatment can improve mental health outcomes.- The event rate for suicide in clinical trials is very low.- Monitoring for mental health issues is crucial in psoriasis treatment. Chapters 00:00 - Understanding Latent Tuberculosis in Dermatology08:40 - Mental Health and Psoriasis: A Critical Connection

Summary In this episode of the Future of Dermatology podcast, Dr. Faranak Kamangar chats with Soroush Aboutalebi about his personal skin journey with a genetic condition called congenital ichthyosiform erythroderma, and the importance of community support through Camp Wonder. They discuss the challenges of managing skin conditions, the significance of compounding in dermatology, and the transformative experiences at Camp Wonder that help children build confidence and connect with others facing similar challenges. The conversation also touches on the future of dermatology, including exciting innovations in treatments and the role of dermatologists in patient care. Learn more about Camp Wonder: https://www.csdf.org/ Takeaways - Soroush Aboutalebi shares his journey with congenital ichthyosiform erythroderma.- Managing a skin condition can be challenging but also empowering.- Compounding medications have become less accessible in recent years.- Camp Wonder provides a supportive environment for children with skin conditions.- Building confidence is a key benefit of attending Camp Wonder.- Dermatologists play a vital role in the care provided at Camp Wonder.- Involvement in Camp Wonder can be through volunteering or donations.- The future of dermatology holds promise with new treatments and technologies.- Genetic therapies are on the horizon for skin conditions.- Community support is essential for individuals with skin diseases. Chapters 00:00 - Introduction to the Future of Dermatology Podcast00:54 - Soroush Aboutalebi's Skin Journey05:06 - The Importance of Compounding in Dermatology08:08 - Camp Wonder: A Safe Haven for Kids with Skin Conditions10:49 - Building Confidence Through Camp Experiences13:46 - The Role of Dermatologists at Camp Wonder16:16 - Getting Involved with Camp Wonder20:14 - Future of Dermatology: Hope for New Treatments

Summary This episode of The Future of Dermatology Podcast delves into various aspects of eczema management, exploring personal experiences, treatment options, and future research directions. Dr. Larry Eichenfield uses metaphors of tools to describe their approach to managing eczema, emphasizing the importance of having a variety of strategies at their disposal. Takeaways - Eczema management requires a toolbox of strategies.- Personal experiences can shape treatment approaches.- Understanding different treatment options is crucial.- Future research may lead to better eczema solutions.- Metaphors can help explain complex health issues.- Community support plays a role in managing eczema.- Education about eczema is essential for patients.- Innovative treatments are on the horizon.- Holistic approaches can complement traditional treatments.- Individualized care is key to effective management. Chapters 00:00 - Introduction to Topical Steroid Withdrawal

Summary In this truncated replay from the 2025 SF Derm Annual Conference, Dr. Victor Huang delves into the misconceptions surrounding vitiligo, emphasizing that it is often viewed merely as a cosmetic issue. This perception significantly impacts insurance coverage and the availability of care for those affected by the condition. The presentation highlights the need for a shift in understanding among policymakers and insurance companies to ensure proper treatment and support for individuals with vitiligo. Takeaways - Vitiligo is often misunderstood as just a cosmetic issue.- This misconception affects insurance coverage for treatment.- Policymakers need to recognize the medical implications of vitiligo.- Insurance companies are excluding vitiligo care from their programs.- There is a need for better education about vitiligo.- The perception of vitiligo impacts patient access to care.- Advocacy is essential for changing policy regarding vitiligo.- Healthcare providers face challenges due to these misconceptions.- Patients with vitiligo deserve comprehensive care.- A shift in perception can lead to better treatment options. Chapters 00:00 - Introduction to Vitiligo and Its Impact00:33 - Understanding the Burden of Vitiligo

Summary In this episode of the Future of Dermatology podcast, guest speaker Dr. Donna Culton, delves into the intricate science of skin diseases, focusing on the pathophysiology of conditions like pemphigoid. The discussion covers the roles of B cells, autoantibodies, and various cellular players in inflammation, as well as the mediators that contribute to symptoms like itch. The episode emphasizes the complexity of these diseases and the potential for new therapeutic targets, while also highlighting the challenges in conducting clinical trials for affected populations. Takeaways - Dr. Culton emphasizes the importance of understanding B cells in skin diseases.- Pemphigus and pemphigoid have distinct clinical presentations and treatments.- Autoantibodies play a crucial role in the pathophysiology of pemphigoid.- Mast cells and eosinophils are key players in the inflammatory response.- Cytokines like IL-4 and IL-5 are critical for B cell activation and eosinophil recruitment.- The itch associated with pemphigoid is complex and not solely due to histamine.- Clinical trials for skin diseases face unique challenges due to patient comorbidities.- Understanding the mediators of degradation can inform treatment strategies.- The complexity of skin diseases allows for multiple therapeutic targets.- This podcast serves as an educational resource for understanding dermatological science. Chapters 00:00 - Introduction to Dermatology and B Cells02:51 - Understanding Pemphigus and Pemphigoid05:25 - The Role of Autoantibodies in Skin Diseases08:20 - Key Cellular Players in Inflammation10:53 - Mediators of Inflammation and Itch13:57 - Pathophysiology and Future Therapies

Summary In this truncated replay, Dr. Shyam Joshi explores the intersection between allergy and dermatology—focusing on how chronic spontaneous urticaria (CSU), atopic dermatitis, and food allergies often overlap. Learn how emerging biologics like omalizumab and dupilumab are reshaping treatment decisions, why comorbidities matter, and how collaboration between allergists and dermatologists creates better outcomes for patients with complex allergic and dermatologic conditions. This episode dives into real-world case studies, FDA updates on antihistamines, and the multidisciplinary approach to managing eczema and CSU in pediatric and adult populations. Takeaways - FDA Advisory on Antihistamines: Long-term use of cetirizine or levocetirizine can lead to rebound pruritus upon discontinuation—but gradual tapering minimizes symptoms.- Biologic Selection Depends on Comorbidities:- Omalizumab is effective for IgE-mediated food allergies and chronic urticaria.- Dupilumab is preferred for patients with eosinophilic esophagitis (EoE) or moderate-to-severe atopic dermatitis.- CSU Is Systemic: Symptoms may extend beyond hives—impacting joints, sleep, and energy levels.- Comorbid Conditions Are Common: Up to 20 % of CSU patients have asthma, allergic rhinitis, or food allergies; identifying these helps guide treatment and patient education.- Unified Messaging Builds Trust: Consistent communication from both dermatologists and allergists reduces unnecessary testing and supports adherence to treatment plans. Chapters 00:00 - Introduction: Bridging Allergy and Dermatology00:45 - Case Study: An 18-Year-Old with Chronic Urticaria02:00 - FDA Warning: Antihistamine Withdrawal Itch03:45 - Selecting the Right Biologic: Food Allergy Considerations04:45 - Eosinophilic Esophagitis and CSU 05:35 - The Systemic Nature of CSU06:40 - Comorbidities in CSU and Atopic Patients07:30 - Multidisciplinary Collaboration in Practice08:00 - Closing Thoughts & Educational Disclaimer